Patents by Inventor Karl J. Guegler

Karl J. Guegler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SH3-containing proteins
    Patent number: 5916753
    Abstract: The invention provides a human SH3-containing protein (HS3C) and polynucleotides which identify and encode HS3C. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HS3C.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: June 29, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Preeti Lal
  • Human ena/VASP-like protein splice variant
    Patent number: 5912128
    Abstract: The invention provides a human ena/VASP-like protein splice variant (EVL1) and polynucleotides which identify and encode EVL1. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of EVL 1.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: June 15, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
  • Human Homolog of the rat G protein gamma-5 subunit
    Patent number: 5912130
    Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a G protein gamma subunit (gpg) which was isolated from human pituitary gland. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding GPG and for gpg antisense molecules. The invention also provides for purified GPG; antibodies, antagonists and inhibitors which specifically bind GPG; and pharmaceutical compositions and methods of treatment based on GPG antagonists and inhibitors. The invention provides for diagnostic assays which utilize diagnostic compositions comprising nucleic acid sequences, or complements thereof, encoding GPG, purified GPG to be used as a positive control, and antibodies which specifically bind to GPG.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: June 15, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Susan G. Stuart, Lynn E. Murry, Karl J. Guegler, Jeffrey J. Seilhamer
  • Edg-1-receptor homolog
    Patent number: 5912144
    Abstract: The present invention provides a new edg-1 like receptor (NEDG) and polynucleotides which identify and encode NEDG. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of NEDG.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: June 15, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Karl J. Guegler
  • ATP-dependent RNA helicase protein
    Patent number: 5888792
    Abstract: The invention provides a human ATP-dependent RNA helicase (ADRH-1) and polynucleotides which identify and encode ADRH-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ADRH-1.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: March 30, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Neil C. Corley, Purvi Shah
  • Human lysophosphatidic acid acyltransferase
    Patent number: 5888793
    Abstract: The invention provides a human lysophosphatidic acid acyltranferase (HLPAAT) and polynucleotides which identify and encode HLPAAT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HLPAAT.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: March 30, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Karl J. Guegler, Neil C. Corley
  • Disease associated protein kinases
    Patent number: 5885803
    Abstract: The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: March 23, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Preeti Lal, Surya K. Goli, Purvi Shah
  • Human extracellular matrix proteins
    Patent number: 5872234
    Abstract: The invention provides two human extracellular matrix proteins (ECMP) and polynucleotides which identify and encode ECMP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ECMP.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: February 16, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Neil C. Corley, Karl J. Guegler
  • Human Protein Kinases
    Patent number: 5863780
    Abstract: The present invention provides novel human protein kinases (HPK) and polynucleotides which identify and encode HPK. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPK. The invention also provides for pharmaceutical compositions comprising HPK or antagonists of HPK, and antibodies which specifically bind HPK. Additionally, the invention provides antisense molecules to HPK for treatment or prevention of diseases associated with abnormal expression of HPK.
    Type: Grant
    Filed: September 12, 1996
    Date of Patent: January 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Karl J. Guegler, Phillip R. Hawkins
  • Polynucleotides encoding a CD53-like transmembrane protein
    Patent number: 5854022
    Abstract: The present invention provides a human transmembrane protein (ONMO) and polynucleotides which identify and encode ONMO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing ONMO and for treating or preventing disorders associated with expression of ONMO.
    Type: Grant
    Filed: May 13, 1997
    Date of Patent: December 29, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Olga Bandman, Surya K. Goli, Karl J. Guegler
  • Human tumor-associated Kazal inhibitor-like polypeptides and encoding polynucleotides
    Patent number: 5851987
    Abstract: The present invention provides a human tumor-associated Kazal inhibitor (HuKI) and polynucleotides which identify and encode HuKI. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of HuKI, as well as diagnostic assays.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: December 22, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Purvi Shah
  • Human growth-related CDC10 homolog
    Patent number: 5849556
    Abstract: The invention provides a human growth-related CDC10 homolog (GR-SEP) and polynucleotides which identify and encode GR-SEP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of GR-SEP.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: December 15, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Henry Yue, Karl J. Guegler, Matthew R. Kaser, Preete Mathur
  • Human 3-hydroxyisobutyryl-coenzyme a hydrolase
    Patent number: 5849498
    Abstract: The present invention provides a human 3-hydroxyisobutyryl-coenzyme A hydrolase (HIBCOH) and polynucleotides which identify and encode HIBCOH. The invention also provides expression vectors, host cells, and antibodies. The invention also provides methods for the prevention and treatment of diseases associated with expression of HIBCOH, as well as diagnostic assays.
    Type: Grant
    Filed: May 16, 1997
    Date of Patent: December 15, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Karl J. Guegler, Neil C. Corley, Purvi Shah
  • Human map kinase homolog
    Patent number: 5846778
    Abstract: The present invention provides nucleic acid and amino acid sequences that identify and encode a novel human map kinase homolog (SMAP) expressed in cells of the human stomach. The present invention also provides for PCR oligomers or hybridization probes for the detection of nucleotide sequences encoding SMAP or SMAP-like molecules, antisense molecules to the nucleotide sequences which encode SMAP, diagnostic tests based on SMAP encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified SMAP, antibodies capable of binding specifically to SMAP, and agonists and inhibitors with specific binding activity for the polypeptide SMAP.
    Type: Grant
    Filed: August 28, 1997
    Date of Patent: December 8, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Janice Au-Young, Karl J. Guegler, Craig G. Wilde
  • Rab protein
    Patent number: 5843717
    Abstract: The present invention provides a human novel RAB protein (SRAB) and polynucleotides which identify and encode SRAB. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of SRAB.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: December 1, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Karl J. Guegler
  • Chemokine expressed in inflamed adenoid
    Patent number: 5844084
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically to ADEC, hybridization probes or oligonucleotides for the detection of ADEC-encoding nucleotide sequences, genetically engineered host cells for the expression of ADEC, diagnostic tests for inflammation or disease based on ADEC-encoding nucleic acid molecules or antibodies capable of binding specifically to ADEC.
    Type: Grant
    Filed: May 23, 1997
    Date of Patent: December 1, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Karl J. Guegler, Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • DNA encoding a histamine H2 receptor
    Patent number: 5817480
    Abstract: The present invention provides a novel histamine H2 receptor (H2RH) and polynucleotides which identify and encode H2RH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding H2RH and a method for producing H2RH. The invention also provides for agonists, antibodies, or antagonists specifically binding H2RH, and their use, in the prevention and treatment of diseases in which H2RH is expressed. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding H2RH for the treatment of diseases associated with the expression of H2RH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding H2RH.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: October 6, 1998
    Assignee: Incyte Pharmaceuticals
    Inventors: Lynn E. Murry, Janice Au-Young, Karl J. Guegler, Surya K. Goli
  • Disease related nucleotide kinases
    Patent number: 5817482
    Abstract: The invention provides human nucleotide kinases and polynucleotides which identify and encode DRNK. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of DRNK.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: October 6, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Jennifer L. Hillman, Phillip R. Hawkins, Karl J. Guegler, Neil C. Corley
  • Human homolog of the rat G protein gamma-5 subunit
    Patent number: 5783418
    Abstract: The present invention provides a nucleic acid sequence which identifies and encodes a G protein gamma subunit (gpg) which was isolated from human pituitary gland. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding GPG. The invention also provides for purified GPG.
    Type: Grant
    Filed: February 27, 1996
    Date of Patent: July 21, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Susan G. Stuart, Lynn E. Murry, Karl J. Guegler, Jeffrey J. Seilhamer
  • Chemokine expressed in a mixed lymphocyte reaction
    Patent number: 5780268
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode TMEC, a novel human lymphotactin expressed in T-cell mixed lymphocyte reaction (TMLR). The present invention also provides for polymerase chain reaction oligomers or hybridization probes for the detection of nucleotide sequences encoding TMEC or TMEC-like molecules, antisense molecules to the nucleotide sequences which encode TMEC, diagnostic tests based on TMEC encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified TMEC, antibodies capable of binding specifically to TMEC, antagonists and inhibitors with specific binding activity for TMEC, and treatment methods.
    Type: Grant
    Filed: December 6, 1995
    Date of Patent: July 14, 1998
    Assignee: Incyte Pharmaceuticals
    Inventors: Roger Coleman, Karl J. Guegler, Jeffrey J. Seilhamer